Head-To-Head Review: Sintx Technologies (NASDAQ:SINT) versus Edwards Lifesciences (NYSE:EW)

Sintx Technologies (NASDAQ:SINT) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Sintx Technologies and Edwards Lifesciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1	0	1	0	2.00
Edwards Lifesciences	1	10	14	3	2.68

Sintx Technologies currently has a consensus target price of $25.00, suggesting a potential upside of 674.23%. Edwards Lifesciences has a consensus target price of $91.39, suggesting a potential upside of 7.21%. Given Sintx Technologies’ higher possible upside, equities research analysts plainly believe Sintx Technologies is more favorable than Edwards Lifesciences.

Volatility and Risk

Sintx Technologies has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.

Earnings and Valuation

This table compares Sintx Technologies and Edwards Lifesciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$2.89 million	4.11	-$11.02 million	($5.66)	-0.57
Edwards Lifesciences	$5.88 billion	8.41	$4.17 billion	$2.32	36.74

Edwards Lifesciences has higher revenue and earnings than Sintx Technologies. Sintx Technologies is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

18.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by insiders. Comparatively, 1.3% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Sintx Technologies and Edwards Lifesciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-775.12%	-218.25%	-95.06%
Edwards Lifesciences	72.96%	15.01%	11.56%

Summary

Edwards Lifesciences beats Sintx Technologies on 13 of the 15 factors compared between the two stocks.

About Sintx Technologies

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.